Center-Authored Papers

Filters: Author is Gulati, Roman  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.  2012.  Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(15):1864-70. Abstract
X
Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R.  2013.  Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial.. Journal of the National Cancer Institute. Abstract
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter BH, Etzioni R.  2012.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19):5471-5478. Abstract
W
Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B et al..  2013.  Single cell transcriptomic analysis of prostate cancer cells.. BMC molecular biology. 14:6. Abstract
T
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.  2017.  Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. Abstract
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A et al..  2017.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.. Annals of internal medicine. Abstract
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
S
Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery BR, Yu EY, Cheng HH.  2016.  Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.. Medical oncology (Northwood, London, England). 33(7):77. Abstract
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR.  2013.  Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia? American journal of epidemiology. Abstract
R
Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R.  2016.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.. JAMA oncology. Abstract
P
Pritchard CC, Mateo J, Walsh MF, DeSarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. The New England journal of medicine. 375(5):443-453. Abstract
Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S.  2014.  Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International journal of cancer. Journal international du cancer. Abstract
N
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT et al..  2013.  Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.. PloS one. 8(10):e78881. Abstract
M
Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M.  2016.  A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer.. The Prostate. Abstract
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D et al..  2014.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(3):229-37. Abstract
Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E et al..  2014.  Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.. PloS one. 9(10):e111545. Abstract
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R et al..  2017.  Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T.  2010.  Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.. Anti-cancer drugs. 21(4):423-32. Abstract
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV.  2010.  Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos.. The American journal of clinical nutrition. 91(3):777-85. Abstract
L
Lewinshtein D, Gulati R, Nelson PS, Porter CR.  2012.  Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.. BJU international. 109(5):706-12. Abstract
Lawless M, Gulati R, Tretiakova M.  2017.  Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting risk of progression.. Histopathology. Abstract
Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EAM, Pabiniak C, van Ballegooijen M et al..  2014.  Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.. Annals of internal medicine. 161(2):104-12. Abstract
Lange JM, Trock BJ, Gulati R, Etzioni R.  2017.  A Framework for Treatment Decision Making at Prostate Cancer Recurrence.. Medical decision making : an international journal of the Society for Medical Decision Making. :272989X17711913. Abstract